NervGen Pharma to Present at Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury Page 1

Vancouver, British Columbia–(Newsfile Corp. – September 20, 2024) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF)NervGen, Inc., a clinical-stage biotechnology company focused on developing innovative solutions for the treatment of nervous system damage, today announced that Daniel Mikol, MD, Ph.D., Chief Medical Officer of NervGen, will deliver an oral presentation at the Unite 2 Fight Paralysis (U2FP) 19th Annual Science & Advocacy Symposium, taking place September 27-28, 2024 in Atlanta, Georgia. Dr. Mikol will present on “Clinical trials in spinal cord injury…Lost in translation?” during Session 6 on Saturday, September 28 from 11:00 am – 11:20 am EDT at the Atlanta Marriott Marquis.

“There are many challenges in translating results from animal models of spinal cord injury (SCI) to clinical trials in humans with SCI,” said Dr. Mikol. “I am honored to have been invited to speak at this meeting and look forward to highlighting some of these challenges, as well as considerations for how clinical translation might be more successful.”